Akèy › Kansè ovè › Texas › Austin
Etid klinik pou Kansè ovè nan Austin, TX
17 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Austin (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Austin, Austin
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- New Experimental Therapeutics - NEXT Oncology, Austin
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology, Austin
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Ap rekriteFaz 2
- Texas Oncology-Austin North /ID# 279958, Austin
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Texas Oncology - Austin Central /ID# 275046, Austin
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- USO-Texas Oncology-Central/South Texas, Austin
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 2
- Texas Oncology-Austin Center, Austin
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ap rekriteFaz 3
- Texas Oncology - Central/South Texas ( Site 8009), Austin
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology - Austin, Austin
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- Texas Oncology - Central / South Texas, Austin
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Texas Oncology - Central/South Texas, Austin
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Ap rekriteFaz 3
- Texas Oncology - Central South, Austin
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Austin, Austin
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Elligo Health Research, Inc., Austin
Sample Collection for Ongoing Research and Product Evaluation Study
Ap rekriteEtid obsèvasyon
- Natera, Inc., Austin
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Austin
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #4, Austin
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan Austin
- Kansè Poumon ki pa ti selil30 etid
- Kansè (tout kalite)20 etid
- Obèsite20 etid
- Kansè kolorektal19 etid
- Kansè Metastatik19 etid
- Sipwa18 etid
- Ensifizyans kadyak18 etid
- Kansè nan tete18 etid
- Kansè Endomèt15 etid
- Kansè pwostat15 etid
- Depresyon14 etid
- Skizofreni13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.